An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

计划入组 220 人 · 首次发布于 2019 年 11 月 18 日

The CorEvitas Psoriasis (PSO) Registry

计划入组 10,000 人 · 首次发布于 2016 年 3 月 14 日

A Phase 2 Study of HB0017 in Psoriasis Patients

计划入组 200 人 · 首次发布于 2024 年 9 月 19 日

AL101-PSO

1-naphthaleneacetic acid

C₁₂H₁₀O₂

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

Deucravacitinib Shows Efficacy in Psoriasis Patients Who Failed Apremilast Treatment

Novel Oral Psoriasis Therapies Show Promise: TYK2 Inhibitors Lead Breakthrough Advances

Deucravacitinib Demonstrates Long-Term Efficacy and Safety in Psoriasis Treatment